The Trump Administration's move to dismiss or transfer a mifepristone case is not the worst outcome for industry, but still leaves some overhanging risk. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
